18.49
0.05%
0.11
Precedente Chiudi:
$18.38
Aprire:
$18.41
Volume 24 ore:
15,275
Relative Volume:
0.06
Capitalizzazione di mercato:
$1.00B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-17.35%
1M Prestazione:
-18.19%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Nome
Bicara Therapeutics Inc
Settore
Industria
Telefono
617-785-8308
Indirizzo
245 MAIN STREET, CAMBRIDGE
Confronta BCAX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
BCAX | 18.50 | 1.00B | 0 | 0 | 0 | 0.00 |
VRTX | 447.53 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 741.03 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.31 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.73 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.47 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Bicara Therapeutics Inc Borsa (BCAX) Ultime notizie
First Turn Management LLC Takes $14.32 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap DownWhat's Next? - MarketBeat
FY2024 EPS Estimates for BCAX Cut by Cantor Fitzgerald - Defense World
FY2024 EPS Estimates for BCAX Reduced by Cantor Fitzgerald - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 6.2%Here's Why - MarketBeat
Bicara Therapeutics Reports Strong IPO and Clinical Advancements - TipRanks
Bicara Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Bicara Therapeutics: Newly Minted Upsized IPO With Positive Early Data (NASDAQ:BCAX) - Seeking Alpha
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Bicara's $362M IPO Success Powers Cancer Drug Trial with 64% Response Rate | BCAX Stock News - StockTitan
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference - The Manila Times
Bicara Therapeutics (NASDAQ:BCAX) Rating Increased to Strong-Buy at RODMAN&RENSHAW - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.33 Consensus Target Price from Analysts - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Upgraded to "Strong-Buy" at RODMAN&RENSHAW - MarketBeat
Bicara Therapeutics stock gets Buy rating from H.C. Wainwright on asset - Investing.com
Rodman & Renshaw Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat
Biocon Stole Licensed Cancer Biotech to Fuel Spinoff, Suit Says - Bloomberg Law
Morgan Stanley spotlights 10 small-cap stocks with at least 50% upside - Kursiv Media
Bicara Therapeutics (NASDAQ:BCAX) Trading Up 7.9%Should You Buy? - MarketBeat
Balance Sheet Breakdown: Bicara Therapeutics Inc. (BCAX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
In the Green: Bicara Therapeutics Inc. (BCAX) Closes at 19.00, Up/Down -6.40 from Previous Day - The Dwinnex
Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week LowWhat's Next? - MarketBeat
Down rounds don’t aid post-IPO performance - BioCentury
Bicara shares initiated with Buy on cancer drug potential By Investing.com - Investing.com South Africa
Bicara stock poised for growth with late-stage transition, Morgan Stanley optimistic - Investing.com
Bicara Therapeutics stock sees upside with lead drug potential, says Stifel - Investing.com
Bicara shares initiated with Buy on cancer drug potential - Investing.com India
Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating - Investing.com
Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating By Investing.com - Investing.com South Africa
Bicara Therapeutics stock sees upside with lead drug potential, says Stifel By Investing.com - Investing.com South Africa
Three startups aim to raise $400 mln as US biotech IPOs gain traction - Reuters
Bicara Leads Trio of US Biotech IPOs Raising $703 Million - MSN
Market Update: Bicara Therapeutics Inc. (BCAX) Sees Negative Movement, Closing at 24.43 - The Dwinnex
Bicara Therapeutics, Adecoagro, and More Stocks See Action From Activist Investors - MSN
Kiran Mazumdar-Shaw’s niece makes debut at Nasdaq as Bicara Therapeutics goes public - The Financial Express
With IPO, have the capital and resources for clinical studies: Bicara CEO - The Economic Times
Bicara Therapeutics Rings the Opening Bell - Nasdaq
Bicara Therapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Biotech IPO Shares Climb in Debuts After Deals Upsized - MSN
TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc - GuruFocus.com
James E. Flynn Buys 70,000 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock - Defense World
Upstream Bio goes public amid spate of IPOs - The Pharma Letter
Ra Capital Management, L.P. Purchases 1,833,000 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock - Defense World
Ra capital executives buy Bicara Therapeutics shares for $32.99m By Investing.com - Investing.com Canada
Ra capital executives buy Bicara Therapeutics shares for $32.99m - Investing.com India
FMR LLC Acquires New Stake in Bicara Therapeutics Inc - Yahoo Finance
Deerfield entities buy Bicara Therapeutics shares worth $1.26m By Investing.com - Investing.com Australia
Deerfield entities buy Bicara Therapeutics shares worth $1.26m - Investing.com
Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity - Yahoo Finance
Bicara Therapeutics Inc Azioni (BCAX) Dati Finanziari
Non sono disponibili dati finanziari per Bicara Therapeutics Inc (BCAX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Bicara Therapeutics Inc Azioni (BCAX) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Flynn James E | Possible Members of 10% Group |
Sep 17 '24 |
Buy |
18.00 |
70,000 |
1,260,000 |
897,587 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):